Escrito por estudiantes que aprobaron Inmediatamente disponible después del pago Leer en línea o como PDF ¿Documento equivocado? Cámbialo gratis 4,6 TrustPilot
logo-home
Document preview thumbnail
Vista previa 4 fuera de 36 páginas
Examen

NR 668 CEA Final 2026/2027 – Chamberlain University PMHNP Psychopharmacology & Neuroscience Practice Questions with Verified Answers

Document preview thumbnail
Vista previa 4 fuera de 36 páginas

This focused practice question bank is specifically designed for the NR 668 Clinical Evaluation and Assessment (CEA) Final at Chamberlain University, offering advanced coverage of Psychopharmacology and Neuroscience content for the 2026/2027 academic year. This high-yield resource addresses all essential topics related to psychiatric pharmacotherapy and neurobiology, including mechanisms of action of antidepressants (SSRIs, SNRIs, MAOIs, TCAs), antipsychotics (typical and atypical), mood stabilizers (lithium, anticonvulsants), anxiolytics and sedative-hypnotics, stimulants and non-stimulants for ADHD, neurobiological underpinnings of psychiatric disorders (depression, schizophrenia, bipolar disorder, anxiety disorders, PTSD, substance use disorders), neurotransmitter systems (dopamine, serotonin, norepinephrine, GABA, glutamate), pharmacodynamics and pharmacokinetics, drug-drug interactions and adverse effects, prescribing considerations across the lifespan, monitoring parameters and laboratory testing, and integration of psychopharmacology with psychotherapy and psychosocial interventions. Each question is paired with verified answers and detailed rationales to strengthen clinical reasoning, reinforce advanced practice knowledge, and ensure thorough preparation for this capstone examination. Developed exclusively for Chamberlain PMHNP students preparing for the NR 668 CEA Final, this psychopharmacology and neuroscience question bank serves as an essential tool for targeted exam readiness. By engaging with these exam-aligned questions and studying the accompanying rationales, candidates can systematically evaluate their knowledge, identify areas requiring additional review, and build the confidence necessary to succeed on the CEA Final. This resource is vital for demonstrating competency in psychopharmacology, neurobiology, and psychiatric medication management in advanced practice psychiatric nursing. Vertical Keywords NR 668 CEA Final Chamberlain University PMHNP Psychopharmacology Practice Questions Neuroscience PMHNP Psychiatric Medication Management Antidepressant Mechanisms Antipsychotic Pharmacology Neurotransmitter Systems PMHNP Capstone Exam Psychotropic Drug Interactions Verified NR 668 Answers CEA Final Exam Prep

Vista previa del contenido

PMHNP BOARD

PASS.
CHAMBERLAIN UNIVERSITY · COLLEGE OF NURSING


NR 668 CEA Final — Part 2
Practice Question Bank

Psychopharmacology, Neuroscience & Psychiatric Disorders



COMPREHENSIVE REVIEW:
Medication Management, Neuroanatomy & Psychotherapy
— DSM-5 Diagnoses & Clinical Decision-Making



CEA Final Part 2 — Edition 1 · July 2026




EXAM FOCUSED DETAILED 90+ QUESTIONS BUILD CONFIDENCE
RATIONALES
Aligned with NR 668 CEA Complete psychopharm & Pass your NR 668 CEA Final
objectives Clear explanations for mastery neuro coverage




P r e pa r e · P r a c t i c e · Pa s s

Excellence in PMHNP Certification

,NR 668 CEA FINAL — PART 2 QUESTIONS 1–30



Section 1: Substance Use, Psychotherapy & Mental Status Exam


1 A 26-year-old female with 6-year opioid use disorder on buprenorphine
for 4 months is in early remission. She questions continuing
buprenorphine. What is the best course of action?

A Educate the patient on the benefit of continuing buprenorphine for 1-2
more years
B Discontinue buprenorphine and follow serial urine drug screens
C Explore changing from buprenorphine to methadone
D Taper buprenorphine over 2 months as the patient requests


CORRECT ANSWER: A

RATIONALE: Early remission does not mean cure — buprenorphine
maintenance for 1-2 more years reduces relapse risk and supports sustained
recovery. Premature discontinuation significantly increases relapse
potential. The patient's functional improvement is evidence the medication
is working, not that it is no longer needed.

,2 A 30-year-old man with schizoaffective disorder received court-ordered
Zyprexa Relprevv. He states he knows smoking can "make him need more
medication." Which stage of change is he in?

A Contemplation — aware of the problem and considering change
B Action — actively making changes
C Preparation — planning to take action soon
D Maintenance — sustaining changes over time


CORRECT ANSWER: A

RATIONALE: Contemplation involves recognizing a problem and
considering the possibility of change without yet committing to action. The
patient acknowledges smoking affects his medication needs but has not yet
taken steps to quit — this is classic contemplation.




3 A 16-year-old client Jamie states "I might be transgender" and prefers
pronouns "They." The PMHNP recognizes Jamie:

A Identifies as non-binary — not identifying exclusively with male or female
gender
B Identifies as cisgender
C Identifies as gender binary
D Identifies as none of these


CORRECT ANSWER: A

RATIONALE: Non-binary individuals do not identify exclusively as male or
female. They/them pronouns are commonly used by non-binary persons.
Cisgender means identifying with the sex assigned at birth. Gender binary
refers to the traditional male/female dichotomy.

, 4 Which immediate determinant related to relapse prevention is the
biggest predictor of relapse?

A Negative emotional state
B Ineffective coping skills
C Previous history of lapse
D Outcome expectancy


CORRECT ANSWER: A

RATIONALE: Negative emotional states (stress, anger, depression, anxiety)
are the strongest immediate predictors of relapse across substance use
disorders. While ineffective coping and previous lapses contribute, the
acute experience of negative affect most directly triggers return to use.




5 The mental status exam includes all of the following EXCEPT:

A Cranial nerves and reflexes — these are part of the neurological exam, not
the MSE
B Mood and affect
C Appearance and behavior
D Insight and judgment


CORRECT ANSWER: A

RATIONALE: The MSE assesses current mental functioning: appearance,
behavior, mood, affect, speech, thought process, thought content,
perception, cognition, insight, and judgment. Cranial nerves and reflexes
belong to the neurological examination, which is a separate assessment.

Información del documento

Subido en
24 de julio de 2026
Número de páginas
36
Escrito en
2025/2026
Tipo
Examen
Contiene
Preguntas y respuestas
$13.49

¿Documento equivocado? Cámbialo gratis Dentro de los 14 días posteriores a la compra y antes de descargarlo, puedes elegir otro documento. Puedes gastar el importe de nuevo.
Escrito por estudiantes que aprobaron
Inmediatamente disponible después del pago
Leer en línea o como PDF

Seller avatar
Los indicadores de reputación están sujetos a la cantidad de artículos vendidos por una tarifa y las reseñas que ha recibido por esos documentos. Hay tres niveles: Bronce, Plata y Oro. Cuanto mayor reputación, más podrás confiar en la calidad del trabajo del vendedor.
DrEmma
4.1
(8)
Vendido
59
Seguidores
2
Artículos
1568
Última venta
5 horas hace


Por qué los estudiantes eligen Stuvia

Creado por compañeros estudiantes, verificado por reseñas

Calidad en la que puedes confiar: escrito por estudiantes que aprobaron y evaluado por otros que han usado estos resúmenes.

¿No estás satisfecho? Elige otro documento

¡No te preocupes! Puedes elegir directamente otro documento que se ajuste mejor a lo que buscas.

Paga como quieras, empieza a estudiar al instante

Sin suscripción, sin compromisos. Paga como estés acostumbrado con tarjeta de crédito y descarga tu documento PDF inmediatamente.

Student with book image

“Comprado, descargado y aprobado. Así de fácil puede ser.”

Alisha Student

Preguntas frecuentes